AuditLine › HHS OIG › Centers for Medicare and Medicaid Services
HHS OIG recommendation 23-E-05-042.01
CMS should pursue one or more payment changes that could further realize savings from biosimilars for Part B and enrollees.
The recommendation, in the publisher's words
CMS should pursue one or more payment changes that could further realize savings from biosimilars for Part B and enrollees.
- Responsible agency
- Centers for Medicare and Medicaid Services
- Issued
- September 26, 2023
- Report
- Biosimilars Have Lowered Costs for Medicare Part B and Enrollees, but Opportunities for Substantial Spending Reductions Still Exist (OEI-05-22-00140) · find it at HHS OIG
- Kind of report
- Evaluation
- Agency response
- Non-Concur (as recorded by the publisher)
- Last update received
- June 29, 2026
- Next update expected
- July 14, 2027 (publisher's date)
- Publisher flags
- Top recommendation
- Publisher topics
- Financial Stewardship, Prescription Drug
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.